{"organizations": [], "uuid": "a8ef0e4900b8a19d80103769fda36452e92aeab6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180327.html", "section_title": "Archive News &amp; Video for Tuesday, 27 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fda-advisory-committee-votes-in-fa/brief-fda-advisory-committee-votes-in-favor-of-lucemyra-idUSFWN1R90SQ", "country": "US", "domain_rank": 408, "title": "BRIEF-FDA Advisory Committee Votes In Favor Of Lucemyra", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-03-28T04:20:00.000+03:00", "replies_count": 0, "uuid": "a8ef0e4900b8a19d80103769fda36452e92aeab6"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fda-advisory-committee-votes-in-fa/brief-fda-advisory-committee-votes-in-favor-of-lucemyra-idUSFWN1R90SQ", "ord_in_thread": 0, "title": "BRIEF-FDA Advisory Committee Votes In Favor Of Lucemyra", "locations": [], "entities": {"persons": [{"name": "worldmeds", "sentiment": "none"}], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "brief-fda advisory committee votes in favor of lucemyra", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "lucemyra", "sentiment": "none"}, {"name": "on co’s nda", "sentiment": "none"}, {"name": "fda psychopharmacologic drugs advisory committee", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 27 (Reuters) -\n* FDA ADVISORY COMMITTEE VOTES IN FAVOR OF LUCEMYRA™ (LOFEXIDINE) FOR THE MITIGATION OF OPIOID WITHDRAWAL SYMPTOMS\n* US WORLDMEDS - IF APPROVED, LOFEXIDINE WILL BE MARKETED UNDER BRAND NAME LUCEMYRA​\n* US WORLDMEDS - FDA PSYCHOPHARMACOLOGIC DRUGS ADVISORY COMMITTEE VOTED 11 TO 1 TO RECOMMEND LOFEXIDINE APPROVAL FOR MITIGATING OPIOID WITHDRAWAL SYMPTOMS\n* US WORLDMEDS SAYS FDA HAS SET PRESCRIPTION DRUG USER FEE ACT (PDUFA) TARGET ACTION DATE FOR LUCEMYRA IN Q2 2018\n* US WORLDMEDS​ - ‍ADVISORY COMMITTEE’S DISCUSSIONS BASED ON CO’S NDA FOR LUCEMYRA Source text for Eikon:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-28T04:20:00.000+03:00", "crawled": "2018-03-28T19:02:19.005+03:00", "highlightTitle": ""}